Eli Lilly

Business Challenge

Many pharmaceutical manufacturers had invested through the 1980’s and 90’s in high speed, high efficiency lines, built for long, sustained runs. However, the global marketplace is increasing demanding more flexibility, shorter runs, low costs. Ethical Pharma producers are also seeing margins eroded by low cost generics competitors and regulators are driving more diversity into the market; adding further complexity, driving down run lengths, increasing inventories and costs.